Advertisement
"After the payment of all costs associated with the recently completedacquisition of IOMAI Corporation, Intercell's cash position is now more thanEUR 200 m. We also expect our cash position by the end of 2008 to be aroundEUR 200 m. This secures the optimal speed of all development programs and thestrategic growth of the company," states Werner Lanthaler, CFO of Intercell.
Advertisement
About the Intercell-Novartis cooperation
In July 2007, Intercell and Novartis signed a major strategic partnershipto accelerate innovation in the development of vaccines against infectiousdiseases. The partnership grants Novartis option rights to future vaccinecandidates discovered by Intercell during the long-term collaboration.
About Intercell AG
Intercell AG is a growing biotechnology company that designs and developsnovel vaccines for the prevention and treatment of infectious diseases withsubstantial unmet medical needs. The Company's technology platforms include anantigen-discovery system, two proprietary adjuvants and a novel patch-baseddelivery system. Based on these technologies, Intercell has strategicpartnerships with a number of global pharmaceutical companies, includingNovartis, Merck & Co., Inc., Wyeth, Sanofi Pasteur, Kirin and the StatensSerum Institut.
The Company's lead product is a vaccine against Japanese Encephalitis.That vaccine successfully concluded pivotal Phase III clinical trials in 2006,and Intercell is seeking marketing approval in the United States, Europe andCanada. Approval in those markets is anticipated during the second half of2008.
The Company's development pipeline includes Phase II vaccine programs forPseudomonas (in-house development) and S. aureus, which is being developedwith Merck & Co. Inc. The Company's novel Travelers' Diarrhea vaccine patchwill enter Phase III testing in 2009. Intercell is also in clinical trials ofa vaccine enhancement patch with injected pandemic influenza vaccines (oneshot plus patch). In addition, five other products focused on infectiousdiseases are in preclinical development.
Intercell is listed on the Vienna stock exchange under the symbol "ICLL".
For more information, please visit: http://www.intercell.com
This communication expressly or implicitly contains certainforward-looking statements concerning Intercell AG and its business. Suchstatements involve certain known and unknown risks, uncertainties and otherfactors which could cause the actual results, financial condition, performanceor achievements of Intercell AG to be materially different from any futureresults, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of thisdate and does not undertake to update any forward-looking statements containedherein as a result of new information, future events or otherwise.
SOURCE Intercell AG
